STOCK TITAN

iCAD Launches ProFound Insights, ProFound Impact Webinar Series on April 27

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

iCAD announced the launch of a new webinar series called ProFound Insights, ProFound Impact, starting with an event titled “Why Kettering Health Traded out Previous AI Software for ProFound AI®”. The first session is scheduled for April 27, 2022, featuring experts from Kettering Health, an enterprise breast care provider in southwest Ohio. The event will showcase customer success stories, emphasizing the effectiveness of ProFound AI in enhancing reading efficiency and patient care, as noted by Kettering's Director and Medical Director.

Positive
  • Launch of a new webinar series highlighting customer success stories.
  • Kettering Health’s endorsement of ProFound AI for its advanced technology.
  • Positive feedback on ProFound AI's impact on reading efficiency from medical experts.
Negative
  • None.

First event to feature Kettering Health, a leading enterprise breast care provider with 14 breast centers across southwest Ohio

NASHUA, N.H., April 19, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will launch a new webinar series, ProFound Insights, ProFound Impact, which will highlight customer success stories throughout the year. The first event, “Why Kettering Health Traded out Previous AI Software for ProFound AI® Enterprise-Wide” will take place on Wednesday, April 27 from 1-2 pm EDT, featuring distinguished clinical and administrative experts from Kettering Health, a leading enterprise breast care provider with 14 breast centers across southwest Ohio. The event will be moderated by iCAD’s President and CEO, Stacey Stevens. Visit this link to register.

Featured panelists include:

  • Sally Grady, Director of Kettering Health Breast Centers
  • Meghan Musser, DO, Medical Director for Breast Imaging, Kettering Health

“ProFound AI is a game changer. Other AI technologies for DBT seem like smoke and mirrors when compared with ProFound AI. It is clearly the most advanced technology of its kind on the market, and we found it was going to fit well within the other components we offer in our screening program.”– Sally Grady, Director of Kettering Health Breast Centers

“ProFound AI has been something that we as radiologists have started to depend on and really want. Now that we have it available for all our patients coming in, it makes a big difference in our reading efficiency and in the care that we offer. Even the most skeptical of our breast radiologists are now on board with ProFound AI.” -- Meghan Musser, DO, Medical Director for Breast Imaging, Kettering Health

About iCAD, Inc.
Headquartered in Nashua, NH, iCAD® is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.

Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

Contact:
Media Inquiries:
Jessica Burns, iCAD
+1-201-423-4492
jburns@icadmed.com

Investor Inquiries:
iCAD Investor Relations
ir@icadmed.com


FAQ

What is the new webinar series launched by iCAD?

The new webinar series launched by iCAD is called ProFound Insights, ProFound Impact.

When is the first event of the iCAD webinar series taking place?

The first event is scheduled for April 27, 2022.

Who will participate in the iCAD webinar featuring Kettering Health?

The panel will include experts from Kettering Health, including Sally Grady and Meghan Musser, DO.

What technology is Kettering Health using that iCAD promotes?

Kettering Health is using ProFound AI®, which iCAD promotes as an advanced AI solution for breast imaging.

Icad Inc

NASDAQ:ICAD

ICAD Rankings

ICAD Latest News

ICAD Stock Data

46.65M
25.05M
5.63%
27.16%
0.95%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
NASHUA